Signalling Pathways 2014: Information for Media Representatives
Accelerating the pace of translating novel and emerging cancer treatments to the bedside
The ESMO symposium “Signalling Pathways – Targeting the PI3K/AKT/mTOR pathway” is the second ESMO event fully dedicated to personalised medicine. Academic, clinical and industry researchers as well as practicing oncologists working in different tumour settings but sharing common underlining mechanisms and signalling pathways will have the possibility to explore pre-clinical and clinical issues relevant for targeting all axis of the PI3K/AKT/mTOR pathway and discuss around the rationale and possible strategies to inhibit the pathway in multiple diseases.
Around 200 attendees are expected from throughout Europe and the rest of the world.
- Clinical development of PI3K/AKT/mTOR inhibitors
- From pre-clinical setting to phase I studies
- Targeting the axis in the clinic: breast cancer, genitourinary cancers, lymphoma, pNET, lung cancer, gynaecological/endometrial cancers)
- Pathway interaction with other systems
- Efficacy and toxicities of individual inhibitors and combinations
ESMO welcomes media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the ESMO Media Policy.
To register for the event, please complete the Media Registration Form. Media registration in advance is strongly recommended. On-site registration will NOT be possible.
Please contact the ESMO Press Office if you already want to schedule interviews or for any additional question.
ESMO Press Office